Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Cantor Fitzgerald 

Oncolytics Biotech diskutieren

Oncolytics Biotech

WKN: A2JMW5 / Symbol: ONCY / Name: Oncolytics Bio / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

1,61 €
-4,73 %

Oncolytics Biotech Inc. (NASDAQ: ONCY) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,69
Veränderung
Endet am 06.03.24

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 13,75
Veränderung
Endet am 16.08.24

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,67
Veränderung
Endet am 13.11.24

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at HC Wainwright from $15.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,56
Veränderung
Endet am 04.01.25

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,60
Veränderung
Endet am 19.01.25

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,66
Veränderung
Endet am 14.02.25

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 2,76
Veränderung
Endet am 04.04.25

Oncolytics Biotech Inc. (NASDAQ: ONCY) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.
Ratings data for ONCY provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,63
Veränderung
Endet am 14.05.25

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for ONCY provided by MarketBeat